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Background: Clinical evidence increasingly suggests inflammation may be important specifically for an
etiologically distinct depression subtype, characterised by resistance to antidepressant medication.
However, epidemiological investigations of the relationship of inflammation with depression and psy-
chological distress have failed to acknowledge these developments, which may have resulted in bias or
masking of associations driven by the subtype. This may have contributed to inconsistent results in epi-
demiological studies, and equivocal support for an inflammation-depression link.
Methods: An antidepressant-resistant, inflammatory depression subtype would result in stronger associ-
ations of depressive symptomatology with inflammation among antidepressant users than non-users,
due to over-representation of subtype individuals among antidepressant users experiencing severe or
persistent symptoms. We investigate, in a sample of 10,363 UK adults aged 16–98, modification by
antidepressants of cross-sectional and longitudinal associations between C-reactive protein and psycho-
logical distress (General Health Questionnaire score, GHQ). We account for confounding by age, gender,
income, inflammatory somatic illness, body mass index and, in longitudinal models, baseline psycholog-
ical distress. Sensitivity analyses consider smoking, ethnicity, and other medications.
Results: Robust associations of log-CRP and GHQ were seen for antidepressant users but not for non-users
in both cross-sectional (coeff: 0.54, p = 0.01 vs 0.06, p = 0.28) and longitudinal models (coeff: 0.57,
p = 0.006 vs 0.04, p = 0.39 two waves post-baseline). Cross-sectional associations were strongest for tri-
cyclic users, and longitudinal associations strongest for SSRI users. In multilevel, repeated-measures lon-
gitudinal models, associations for antidepressant users peaked two waves after baseline before declining.
Conclusions: Results suggest evidence for existence of an inflammatory depression subtype. Previous
studies’ exclusion of antidepressant users and failure to consider interactive effects may have obscured
associations driven by the subgroup. Follow-up work is now needed in community samples with clinical
depression measures and prescription histories, to further elucidate the mechanisms involved.
 2017 Published by Elsevier Inc.1. Introduction
Depression-like symptoms are produced by acute elevations in
inflammatory activity, either as part of ‘sickness behaviour’ follow-
ing infection or injury, or by experimentally-induced responses to
exogenous inflammatory agents (Miller et al., 2009). The inflam-
matory theory of depression argues that, similarly, depressive
symptoms and syndromes are linked to variations in endogenous
‘systemic’ inflammation, a milder analogue of the acute inflamma-
tory response which occurs in the absence of infection or injury. Inlarge community samples this has been investigated by examining
associations of circulating inflammatory markers with depression
diagnoses or questionnaire-derived psychological distress, concur-
rently or after a follow-up period. However, both cross-sectional
(Dowlati et al., 2010; de Menezes et al., 2017) and longitudinal
community studies (Valkanova et al., 2013; Chocano-Bedoya
et al., 2014; Au et al., 2015; Das, 2016) are equivocal in their sup-
port for an impact of inflammation on depressive symptomatology.
Heterogeneity in results may partly relate to modifying factors
such as age, gender and follow-up time (Das, 2016; Engler et al.,
2016), but clinical work increasingly suggests systemic inflamma-
tion is important specifically for an etiologically distinct depressive
subtype, characterised by poor antidepressant treatment response
(Barnes et al., 2017). Non-response to antidepressants is predictedssants,
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ants associated with elevated inflammation (Baune et al., 2010)
and transcription of genes in the inflammatory cytokine pathway
(Powell et al., 2013), while administration of anti-inflammatory
agents improves treatment response (Raison et al., 2013). Thus,
in epidemiological studies, mixed findings may relate to failure
to consider a distinct inflammatory-depressive ‘immunopheno
type’, which may obscure associations (Barnes et al., 2017). Mean-
while, antidepressants may partly work via anti-inflammatory
actions, since they appear to have anti-inflammatory effects
peripherally and within the brain (Tynan et al., 2012), but certain
antidepressants may promote inflammation, with cross-sectional
CRP elevations net of depressive symptoms reported for tricyclics,
tetracyclics, and serotonin–norepinephrine reuptake inhibitors,
but not SSRIs (Hamer et al., 2011; Vogelzangs et al., 2012).
The relationship between inflammation, depressive symptoma-
tology and antidepressants is therefore complex, possibly modified
further by antidepressant type. If an inflammatory-depressive sub-
type exists characterised by poor antidepressant response, in an
observational study we should expect a stronger inflammation-
depression relationship among antidepressant users compared to
non-users, since individuals with inflammatory depression will
be over-represented among users reporting severe or persistent
symptoms. If antidepressants work via anti-inflammatory effects,
we should expect a weaker relationship among users, as variation
at the high end of the range for both inflammatory markers and
depressive symptoms are reduced together, relative to depressed
but medically untreated individuals. If certain antidepressants
raise inflammatory markers while reducing depressive symptoms,
we should expect weaker inflammation-depression links among
users of those antidepressants specifically.
Epidemiological studies typically exclude antidepressant users
(Camacho et al., 2014; Zalli et al., 2016), or adjust for antidepres-
sants (Gimeno et al., 2009; Das, 2016). If antidepressant use mod-
ifies associations, exclusion will produce biased estimates, while
adjustment without subgroup analysis may obscure associations
concentrated in a small treatment-resistant subgroup. To our
knowledge only one study has considered antidepressant modifi-
cation, reporting a cross-sectional association of the inflammatory
marker C-reactive protein (CRP) with somatic (but not cognitive)
depressive symptoms restricted to non-users of antidepressants.
The authors suggest this supports anti-inflammatory effects of
antidepressants(White et al., 2016), but since participants with
CRP values suggesting current infection were not excluded, associ-
ations may also reflect infection-related sickness behaviour, statis-
tically detectable only in the larger group.
We integrate the hypothesis of the antidepressant-resistant,
inflammatory depression subtype into an epidemiological study.
We investigate modification of cross-sectional and longitudinal
associations of CRP with General Health Questionnaire score, a
measure of psychological distress, by all antidepressants, and by
antidepressant types.2. Methods
The UKHLS is an annual longitudinal survey of over UK 40,000
households, comprising a larger General Population Sample
(GPS), a stratified clustered random sample of households repre-
sentative of the UK population which joined in 2009–10, and a
smaller component from the pre-existing British Household Panel
Survey (BHPS) (Benzeval et al., 2014). Sociodemographic informa-
tion was obtained at annual interviews, and biomedical measures
taken during a nurse visit five months after the wave 2 interview
(W2, GPS participants) or wave 3 interview (W3, BHPS partici-
pants). Respondents were eligible for a biomedical visit if they tookPlease cite this article in press as: Hughes, A., Kumari, M. Associations of C-re
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16+, lived in England, Wales or Scotland, and were not pregnant.
Of these 35875, 57.5% took part.
The initial sample was defined as participants present at the
biomedical assessment and at least one subsequent wave. Partici-
pants were excluded if they had CRP > 10mg/L, usually assumed to
reflect current infection(Pearson et al., 2003). Of these 19,107,
11767 (61.6%) had usable CRP measurements, with missingness
largely due to non-consent for blood sampling. 348 were excluded
for lacking any follow-up GHQ measurements, and 1056 for miss-
ing covariates, leaving 10,363.3. Measures
CRP was analyzed from serum using the N Latex CRP mono
Immunoassay on the Behring Nephelometer II Analyzer (Benzeval
et al., 2014). Psychological distress was measured using the 12-
item General Health Questionnaire (GHQ) (Goldberg et al., 1997).
Participants were asked 12 questions to capture depressive and
anxiety symptoms in the past four weeks, and an overall score
(range 0–36) calculated.
All antidepressants with BNF codes 04.01.01-04.01.04 were
considered, namely tricyclics, selective serotonin reuptake inhibi-
tors (SSRIs), monoamine oxidase inhibitors (MAOIs), and ‘other’
antidepressants (section 04.01.04). 958 participants were taking
antidepressants, most commonly SSRIs (551 participants) followed
by tricyclics (303 participants). 11 were taking MAOIs and 151
other antidepressants. 57 participants were taking two, usually a
tricyclic plus SSRI (N = 38).
All models adjusted for age and gender at biomedical assess-
ment, and age-band specific quartiles of equivalised household
income from W2/W3. Diagnoses at baseline of inflammatory
somatic illness (asthma, emphysema, chronic bronchitis, cancer,
cardiac problems including high blood pressure) were derived
using questionnaire information from UKHLS W1/W2 (GPS partic-
ipants) or BHPS W18 and UKHLS W2 (BHPS participants). Full-
adjusted longitudinal models also included baseline GHQ score
and diagnoses of somatic conditions during follow-up, again using
annual questionnaire information. Baseline BMI was calculated
from height and weight measured by a nurse using a portable sta-
diometer and Tanita-BF522 digital floor scales, and classified as
<18.5, 18.5–24.9, 25.0–29.9, and 30. Anti-inflammatory medica-
tions included non-steroidal anti-inflammatory medications
(NSAIDs), statins, and corticosteroids.4. Analysis
GHQ scores approximated a normal distribution so were
included untransformed in linear regressions; CRP was skewed
and therefore log-transformed. Relationships were examined sepa-
rately by antidepressant use: non-users, all antidepressants, SSRIs,
tricyclics, MAOIs and others, combined treatment. To construct tra-
jectories of CRP-GHQ associations, GHQ scores 1, 2 and 3 waves
post-baseline were modelled as functions of baseline log-CRP,
using an interaction term between log- CRP and waves since base-
line. A repeated-measures, multilevel panel data structure was
used, with measurements 1, 2 and 3 waves later nested within
individuals. Baseline covariates including baseline GHQ were trea-
ted as time-invariant, and new diagnoses during follow-up as
time-varying. Unbalanced data was allowed, meaning participants
were included even if not present at all outcome waves. All analy-
ses used robust standard errors to account for survey effects.
Antidepressant use was considerably more common among
female participants, and related to GHQ score. Thus, to ascertain
whether antidepressant use itself modified associations, weactive protein and psychological distress are modified by antidepressants,
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ipants with clinically relevant GHQ scores following Goldberg
(Goldberg et al., 1997), using both the 3 and 4 cutoffs from 0
to 12 scoring. Further sensitivity analyses adjusted for anti-
inflammatory medications, time of day, season, and processing
time of blood samples, and for smoking, which may be a cause or
consequence of psychological distress (Taylor et al., 2014). A sensi-
tivity analysis exploring impact of ethnicity excluded the 3.7% of
participants defining not as a white group, while another excluded
women taking oral contraceptives (OCs) or hormone replacement
therapy (HRT) Table 1.
5. Results
Compared to non-users, antidepressant users were slightly
older, less affluent and considerably more likely to be female. They
were more likely to be white, current or former smokers, and to
have extreme BMIs (underweight or obese). They were more likely
to take anti-inflammatory medications, OCs or HRT, and have a rel-
evant somatic illness. They had higher CRP and higher GHQ scores
at all waves (all p < 0.05).
In cross-sectional models adjusted for age, gender and house-
hold income (Table 2), CRP was associated with GHQ for all partic-
ipants. For non-users of antidepressants, adjustment for BMI and
long-term illness explained associations. Conversely, a GHQ eleva-
tion for antidepressant users was robust (coeff: 0.54, p = 0.01) and
strongest for tricyclic users (coeff: 1.07, p = 0.006). No significant
associations were seen for other antidepressant types. There wasTable 1
Descriptive characteristics of analytic sample, by antidepressant use (N = 10,363).
None
N = 9405
Any
N = 95
BASELINE CHARACTERSTICS Mean(S.D.) Mean(
GHQc 10.5(4.8) 15.6(7
C-reactive protein 1.95(1.97) 2.65(2
Age (years) 51.7 (16.9) 53.1 (
(%) (%)
Gender Male 46.6 25.9
Female 53.4 74.1
Equivalised household income
quartiles (age-specific)
Highest 26.7 19.0
3 26.2 25.2
2 24.9 26.3
Lowest 22.3 29.5
Ethnicity White 96.0 98.3
Other (incl. mixed) 4.0 1.7
Relevant somatic illness No 72.4 58.5
Yes 27.6 41.5
Smoking Never smoker 54.5 42.9
Ex-smoker 28.2 29.2
Current, 10/day 9.0 11.0
Current, 11–20/day 7.1 12.9
Current, >20/day 1.2 4.0
Body Mass Index (kg/m2) 18.5–24.9 29.6 22.7
25.0–29.9 39.9 31.9
30–34.9 19.2 23.4
>35 8.3 16.6
<18.5 3.1 5.4
NSAIDsd/statins/corticosteroids No 80.9 66.4
Yes 19.1 33.6
Oral Contraceptives /HRT No 94.5 92.8
Yes 5.5 7.2
FOLLOW-UP Mean(S.D.) Mean(
GHQ 1 wave later 10.4(4.9) 14.7(7
GHQ 2 waves later 10.5(5.1) 14.6(7
GHQ 3 waves later 10.6(5.2) 14.4(7
a Selective serotonin reuptake inhibitors.
b Monoamine-oxidase inhibitors.
c General Health Questionnaire Score.
d Non-steroidal anti-inflammatory medications.
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antidepressants with clinically significant GHQ symptoms using
either the lower or the higher threshold (respectively, N = 1816,
coeff: 0.04, p = 0.76; N = 1423, coeff:0.02, CI:0.28–0.24,
p = 0.88). In a whole-sample model, an interaction term for
CRP⁄gender suggested a weaker CRP-GHQ association for women,
but was non-significant (coeff = 0.18, p = 0.08).
Adjustment for smoking made little difference (0.49, p = 0.02
for all antidepressant users; 1.01, p = 0.01 for tricyclics), as did
adjustment for anti-inflammatory medications (0.53, p = 0.001
for all antidepressants, 1.06, p = 0.007 for tricyclics), or time of
day, season and processing time of blood samples (0.53, p = 0.01
for all antidepressants; 1.06, p = 0.007 for tricyclics), excluding
non-white/mixed participants (for all antidepressants, 0.58,
p = 0.007; for tricyclics, 1.10, p = 0.005), or excluding women tak-
ing OCs/HRT (for all antidepressants, 0.52, p = 0.02, for tricyclics,
1.05, p = 0.01).
6. Longitudinal
In longitudinal models adjusted for baseline GHQ, age, gender,
household income, a modest association emerged across the three
years for non-users of antidepressants (coeff: 0.12, p = 0.02 at the
third outcome point), which was explained by addition of BMI
and long-term illness. Among users, there was no association one
or three waves post-baseline, but a sharp peak in associations after
two waves, robust to adjustment for BMI and illness (coeff: 0.57,
p = 0.006). This was strongest for SSRI users (fully-adjusted8
SSRIsa
N = 508
Tricyclics
N = 251
MAOIsb and others
N = 142
Combined
N = 57
S.D.) Mean(S.D.) Mean(S.D.) Mean(S.D.) Mean(S.D.)
.4) 15.4(7.2) 14.2(6.8) 17.4(8.3) 19.3(7.4)
.32) 2.37(2.13) 2.99(2.44) 2.81(2.49) 3.21(2.69)
14.2) 50.4 (13.8) 58.8 (14.2) 52.1(13.0) 53.6(13.1)
(%) (%) (%) (%)
23.2 27.9 31.0 28.1
76.8 72.1 69.0 71.9
19.3 19.5 16.2 21.1
24.8 27.1 25.4 19.3
27.0 24.3 27.5 26.3
28.9 29.1 31.0 33.3
98.6 98.8 96.5 98.2
1.4 1.2 3.5 1.8
65.0 51.0 54.2 43.9
35.0 49.0 45.8 56.1
43.1 43.8 42.3 38.6
29.9 33.1 21.1 26.3
12.2 8.4 10.6 12.3
11.2 11.6 19.7 17.5
3.5 3.2 6.3 5.3
23.2 18.7 26.8 24.6
32.3 35.5 27.5 24.6
22.8 26.3 20.4 22.8
16.5 13.9 19.7 21.1
5.1 5.6 5.6 7.0
73.8 53.0 68.3 54.4
26.2 47.0 31.7 45.6
92.7 94.4 90.9 91.2
7.3 5.6 9.2 8.8
S.D.) Mean(S.D.) Mean(S.D.) Mean(S.D.) Mean(S.D.)
.3) 14.6(7.2) 13.4(6.6) 16.1(8.1) 17.8(7.8)
.3) 14.3(7.1) 13.1(6.2) 16.9(8.3) 18.5(7.7)
.1) 14.2(6.8) 13.1(6.5) 15.8(8.2) 17.8(8.0)
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Table 2
Elevations in GHQa score per unit log-transformed baseline CRP, by antidepressant use.
CROSS-SECTIONAL ASSOCIATIONS*
Coeff CI P Coeff CI P
Non-users 0.13 0.03–0.23 0.01 Non-users 0.06 0.05–0.16 0.28
All types 0.63 0.23–1.05 0.004 All types 0.54 0.12–0.96 0.01
SSRIsb 0.41 0.19–1.01 0.18 SSRIs 0.31 0.28–0.91 0.30
Tricyclics 1.18 0.40–1.95 0.003 Tricyclics 1.07 0.31–1.84 0.006
MAOIsc/Others 0.58 0.46–1.62 0.28 MAOIsc/Others 0.54 0.49–1.58 0.30
Combined 0.37 2.17–1.42 0.68 Combined 0.39 2.16–1.38 0.67
*Adjusted for age, gender, household income *Adjusted for age, gender, household income, long-term illness and BMI
categories
LONGITUDINAL ASSOCIATIONS
Non-users Waves later Coeff CI P Non-users Waves later Coeff CI P
1 0.06 0.03–0.15 0.22 1 0.02 0.07–0.12 0.61
2 0.09 0.01–0.18 0.08 2 0.04 0.06–0.14 0.39
3 0.12 0.02–0.22 0.02 3 0.07 0.04–0.18 0.21
All types Waves later Coeff CI P All types Waves later Coeff CI P
1 0.16 0.24–0.57 0.43 1 0.12 0.28–0.53 0.55
2 0.63 0.22–1.04 <0.001 2 0.57 0.16–0.98 0.006
3 0.09 0.32–0.50 0.66 3 0.04 0.36–0.45 0.84
SSRIs Waves later Coeff CI P SSRIs Waves later Coeff CI P
1 0.22 0.37–0.81 0.47 1 0.17 0.42–0.76 0.57
2 0.84 0.27–1.41 <0.001 2 0.77 0.21–1.34 0.008
3 0.03 0.51–0.57 0.91 3 0.03 0.56–0.50 0.91
Tricyclics Waves later Coeff CI P Tricyclics Waves later Coeff CI P
1 0.00 0.60–0.61 0.99 1 0.02 0.63–0.59 0.95
2 0.16 0.47–0.79 0.62 2 0.12 0.51–0.74 0.72
3 0.20 0.93–0.53 0.59 3 0.24 0.51–0.74 0.52
MAOIsc/Others Waves later Coeff CI P MAOIsc/Others Waves later Coeff CI P
1 0.26 0.88–1.39 0.66 1 0.24 0.88–1.36 0.67
2 0.29 0.85–1.43 0.62 2 0.27 0.85–1.39 0.63
3 0.62 0.56–1.79 0.30 3 0.61 0.56–1.77 0.31
Combined Waves later Coeff CI P Combined Waves later Coeff CI P
1 0.27 2.17–1.64 0.78 1 0.30 2.21–1.60 0.76
2 1.65 0.53–3.83 0.14 2 1.61 0.60–3.83 0.15
3 0.07 1.98–2.13 0.94 3 0.07 1.97–2.11 0.95
*Adjusted for baseline GHQ, age, gender, income *Adjusted for baseline GHQ, age, gender, income, long-term illness, BMI
a General Health Questionnaire.
b Selective serotonin reuptake inhibitors.
c Monoamine-oxidase inhibitors.
4 A. Hughes, M. Kumari / Brain, Behavior, and Immunity xxx (2017) xxx–xxxcoeff = 0.77, p = 0.008), and the small group using multiple antide-
pressants, although estimates for that group were imprecise (fully-
adjusted coeff = 1.61, p = 0.15). The elevation was not explained by
gender interaction (for men and women, elevations were 0.09,
p = 0.20 and 0.13, 0.06 respectively; interaction p = 0.65).
Adjustment for smoking made little difference to year 2 eleva-
tions (0.54, p = 0.009 for all antidepressants; 0.74, p = 0.01 for
SSRIs), as did adjustment for anti-inflammatory medications
(0.56, p = 0.007 for all antidepressants; 0.77, p = 0.008 for SSRIs),
or for time of day, season and processing time of blood samples
(0.57, p = 0.006 for all antidepressants; 0.77, p = 0.008 for SSRIs),
exclusion of non-white/mixed participants (0.56, p = 0.007, for all
antidepressants; 0.76, p = 0.001, for SSRIs) and exclusion of women
taking OCs/HRT (0.63, p = 0.004 for all antidepressants; 0.81,
p = 0.007 for SSRIs).
7. Discussion
Results suggest evidence for existence of an antidepressant-
resistant, inflammatory depression subtype. Cross-sectional asso-
ciations were strongest for users of tricyclics, rather than SSRIs to
which most clinical evidence for the subtype relates. However, tri-
cyclics are not usually prescribed as a first-line antidepressant, and
may have been prescribed because SSRIs were ineffective, thus act-
ing as a better filter for the antidepressant-resistant subtype than
SSRI use. Alternatively, since inflammatory resistance to tricyclics
has not been studied as much as SSRI resistance, inflammatory
activity may also predict non-response to tricyclics.Please cite this article in press as: Hughes, A., Kumari, M. Associations of C-re
supporting an inflammatory depression subtype: Findings from UKHLS. BrainTrajectories of GHQ 1, 2 and 3 waves post-baseline indicate that
the longitudinal relationship of CRP and psychological distress is
also substantially modified by antidepressant use, in particular
SSRIs, for which predictive effects of inflammatory activity on
treatment response are well documented. Among non-users of
antidepressants, that a modest emergent association across the
three-year outcome period was largely explained by BMI and
chronic illness may reflect confounding by these factors, or that
adiposity and chronic illness are key upstream drivers of systemic
inflammation which in turn leads to psychological distress.
The increase for antidepressant users in associations at year 2 is
difficult to explain. Since we have no information on antidepres-
sant use post-baseline, this may relate to treatment secession,
changes in antidepressant dosage or type, or further deterioration
in responsiveness. Similarly, decreased associations at year 3 could
reflect improved symptom management by pharmaceutical or
other means, or baseline inflammation becoming, over time, an
increasingly weak proxy of current inflammation.8. Strengths and limitations
Unlike previous studies, we used data from a nationally-
representative sample across the whole adult age range, consid-
ered modification by several types of antidepressants, and investi-
gated evolution of associations across a three-year outcome period.
However, the GHQ measures psychological distress, and associa-
tions with diagnosed depression may differ. We do not know pre-active protein and psychological distress are modified by antidepressants,
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scribed, limiting the conclusions which can be drawn.
9. Conclusion
This study finds a substantially stronger relationship among
antidepressant users than non-users of an inflammatory marker
with psychological distress. Cross-sectional observations were
strongest for tricyclic users, and longitudinal associations by SSRI
users, indicating the mechanisms involved may be sensitive to
antidepressant type. Results indicate that researchers should be
careful to treat antidepressant use appropriately in epidemiologi-
cal studies of the inflammation-depression link, and may support
existence of an aetiologically distinct, antidepressant-resistant,
inflammatory depression subtype. Further work in community
samples considering diagnosed depression and prescription histo-
ries is now needed to elucidate the mechanisms involved.
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